Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 243

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 243
---
 court to recover an amount in a non-Israeli currency is for the Israeli
court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment,
but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated
in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli
regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.

<div align='center'>146

WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC
a registration statement on Form F-1 under the Securities Act relating to this offering of our Ordinary Shares. This prospectus does
not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain
information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents
of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete
descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may
read the document itself for a complete description of its terms.

Our SEC filings are available
to the public at the SEC’s website at http://www.sec.gov. Upon completion of this offering, we will be subject to the
information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements will
file reports with the SEC. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing
and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act
to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under
the Exchange Act.

We maintain a corporate website
at http://www.regentis.co.il/. Information contained on, or that can be accessed through, our website does not constitute a part
of this prospectus.

<div align='center'>147

REGENTIS BIOMATERIALS LTD.

INTERIM CONDENSED FINANCIAL STATEMENTS

AS OF AND FOR THE SIX MONTHS ENDED